What is IDX?
Founded in 2010, IDX is at the forefront of developing clinically-aligned autonomous algorithms designed to detect diseases from medical images. The company's mission is to democratize healthcare by enabling diagnostic assessments in primary care settings, thereby increasing patient access to high-quality, affordable disease detection. Their flagship product, IDx-DR, is an FDA-cleared AI system capable of detecting diabetic retinopathy and macular edema. IDX is actively expanding its portfolio to include AI-based diagnostic systems for conditions such as macular degeneration, glaucoma, stroke risk, and ear infections, positioning itself as a key innovator in the digital health and medical imaging sectors.
How much funding has IDX raised?
IDX has raised a total of $40M across 4 funding rounds:
Private Equity
$1.4M
Private Equity
$1.1M
Private Equity
$4.5M
Series A
$33M
Private Equity (2012): $1.4M, investors not publicly disclosed
Private Equity (2012): $1.1M, investors not publicly disclosed
Private Equity (2013): $4.6M, investors not publicly disclosed
Series A (2018): $33M, investors not publicly disclosed
What's next for IDX?
With substantial enterprise-level backing and a recent strategic investment, IDX is poised for accelerated growth and market penetration. The company's focus on developing autonomous AI diagnostic tools for critical health conditions suggests a strategic expansion into broader healthcare markets. Future developments are likely to center on further regulatory approvals, scaling commercialization efforts, and forging partnerships within the healthcare ecosystem to integrate their AI solutions into mainstream clinical workflows. This capital infusion will be instrumental in advancing their research and development pipeline and solidifying their position as a leader in AI-powered medical diagnostics.
See full IDX company page
